Novel immunotherapies, including bispecific T-cell engagers, tumor-infiltrating lymphocytes (TILs), and CAR-T cells targeting neuroendocrine-specific antigens such as SSTR2 or CEACAM5, remain in preclinical or early clinical phases, necessitating further validation of safety and efficacy [133,134]. Here, SSTR2 is linked to neoplasm.